Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
Generate Biomedicines, Inc. is an innovative biotechnology company at the forefront of protein therapeutics development, leveraging advanced genetic engineering and artificial intelligence technologies. With its proprietary platform, the firm streamlines the design, optimization, and production of therapeutic proteins, significantly enhancing the efficiency of the drug discovery process while lowering associated costs. Boasting a robust pipeline and strategic partnerships with leading industry players, Generate Biomedicines is poised to deliver groundbreaking treatments that tackle pressing healthcare issues and enhance patient outcomes across multiple therapeutic domains.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$15.39
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Aug 6, 2026 | $-0.48 | $-0.52 | Miss -8.3% | $-0.52 | $5.3M | $6.31M | +19.1% | 1D Pre+1.5% | On-Day-4.1% | 1D Post+3.3% |
Q ended Mar 31, 2026 Reported May 7, 2026 | $-0.51 | $-1.07 | Miss -109.8% | $-1.07 | $5.3M | $7.22M | +36.2% | 1D Pre-0.8% | On-Day-11.2% | 1D Post+0.6% |
Q ended Mar 31, 2025 Report date n/a | — | |||||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| — |
| — |
| — |
| $8.82M |
| — |
| 1D Pre— |
| On-Day— |
| 1D Post— |